Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial

Ilana Graetz; Xin Hu; Rebecca A. Krukowski; Janeane N. Anderson; Edward Stepanski; Gregory Vidal; Teresa M. Waters; Lee S. Schwartzberg

doi:10.1038/s41523-026-00900-9

Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial

Ilana Graetz
, Xin Hu
, Rebecca A. Krukowski
, Janeane N. Anderson
, Edward Stepanski
, Gregory Vidal
, Teresa M. Waters
, Lee S. Schwartzberg

Health Management, Economics, & Policy

Research output: Contribution to journal › Article › peer-review

Abstract

Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.

Original language	English (US)
Article number	33
Journal	npj Breast Cancer
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41523-026-00900-9
State	Published - Dec 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

Access to Document

10.1038/s41523-026-00900-9

Cite this

@article{cf33044c83aa4cd78aa24f5940ae8034,

title = "Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial",

abstract = "Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9\% vs. EUC: 25.0\%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.",

author = "Ilana Graetz and Xin Hu and Krukowski, \{Rebecca A.\} and Anderson, \{Janeane N.\} and Edward Stepanski and Gregory Vidal and Waters, \{Teresa M.\} and Schwartzberg, \{Lee S.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2026.",

year = "2026",

month = dec,

doi = "10.1038/s41523-026-00900-9",

language = "English (US)",

volume = "12",

journal = "npj Breast Cancer",

issn = "2374-4677",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Adherence to oral endocrine therapy by menopausal status

T2 - post hoc insights from a remote monitoring randomized trial

AU - Graetz, Ilana

AU - Hu, Xin

AU - Krukowski, Rebecca A.

AU - Anderson, Janeane N.

AU - Stepanski, Edward

AU - Vidal, Gregory

AU - Waters, Teresa M.

AU - Schwartzberg, Lee S.

PY - 2026/12

Y1 - 2026/12

N2 - Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.

AB - Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.

UR - https://www.scopus.com/pages/publications/105031190397

UR - https://www.scopus.com/pages/publications/105031190397#tab=citedBy

U2 - 10.1038/s41523-026-00900-9

DO - 10.1038/s41523-026-00900-9

M3 - Article

AN - SCOPUS:105031190397

SN - 2374-4677

VL - 12

JO - npj Breast Cancer

JF - npj Breast Cancer

IS - 1

M1 - 33

ER -

Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this